Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEURO-TTRansform
NCT04136184Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Apr 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 16
01
Overview
A Phase 3 trial of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), sponsored by Ionis Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
eplontersen
03
Conditions
hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN)
Beyond the preview
Go deeper on NCT04136184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136184.